1. |
|
2. |
|
3. |
|
4. |
SEMENZATO G. Tumor necrosis factor: a cytokine with multiple biological activities[J]. Br J Cancer,1990,61:354-361..
|
5. |
章敬波,林建银,杨恬.医学细胞分子生物学[M].第1版.北京:中国协和医科大学出版社,2002:6548-5494..
|
6. |
金惠铭,卢建,殷莲华.细胞分子病理生理学[M].第1版.郑州:郑州大学出版社,2002:173-174..
|
7. |
刘红菊,李元桂,毕爱华.肿瘤坏死因子在急性肺损伤发病机制中的作用[J].国外医学免疫分册,1996,(5):229-231..
|
8. |
OKAJIMA K. Regulation of inflammatory responses by endothelial cellsunderstanding the molecular mechanism(s) and its therapeutic application to sepsis[J]. Masui,2008,57(3):311-20..
|
9. |
VELDHUIZEN E J, HAAGSMAN H P. Role of pulmonary surfactant components in surface film formation and dynamics[J]. Biochim Biophys Acta,2000,1467(2):255-270..
|
10. |
BERHANE K, MARGANA R K, BOGGARAM V. Characterization of rabbit SPB promoter region responsive to downregulation by tumor necrosis factoralpha[J]. Am J Physiol Lung Cell Mol Physiol,2000,279(5):L806-814..
|
11. |
MIAKOTINA O L, SNYDER J M. TNFalpha inhibits SPA gene expression in lung epithelial cells via p38 MAPK[J]. Am J Physiol Lung Cell Mol Physiol,2002,283(2):L418-427..
|
12. |
WILCOX P, MILLIKEN C, BRESSLER B. Highdose tumor necrosis factor alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor[J]. Am J Respir Crit Care Med,1996,153(5):1611-1615..
|
13. |
WILCOX P, OSBORNE S, BRESSLER B. Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility[J]. Am Rev Respir Dis,1992,146(2):462-466..
|
14. |
SHERIDAN B C, MCINTYRE R C, MELDRUM D R, et al. Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury[J]. J Surg Res,1997,71(2):150-154..
|
15. |
MEDURI G U, KOHLER G, HEADLEY S, et al. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome[J]. Chest,1995,108(5):1303-1314..
|
16. |
PARSONS P E, MATTHAY M A, WARE L B, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol,2005,288(3):L426-431..
|
17. |
VAN RIEMSDIJKVAN OVERBEEKE I C, BAAN C C, NIESTERS H G M, et al. The TNFalpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity[J]. Eur Heart J,1999,20(11):833-840..
|
18. |
BOYLE E M Jr, CANTY T G Jr, MORGAN E N, et al. Treating myocardial ischemiareperfsion injury by targeting endothelial cell transcription[J]. Ann Thorac Surg,1999,68(5):19491953..
|
19. |
SATO Y, HIRAMATSU Y, HOMMA S, et al. Phosphodiesterase type 4 inhibitor rolipram inhibits actibation of monocytes during extracorporeal circulation[J]. J Thorac Cardiovasc Surg,2005,130(2):346-350..
|
20. |
SOUZA D G, CASSALI G D, POOLE S, et al. Effects of inhibition of PDE4 and TNFα on local and remote injuries following ischaemia and reperfusion injury[J]. Br J Pharmacol,2001,134(5):985-994. doi: 10.1038/sj.bjp.0704336..
|
21. |
MALAZDREWICH C, THUMBIKAT P, ABRAHAMSEN M S, et al. Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxininduced cytokine expression in bovine alveolar macrophages[J]. Microb Pathog,2004,36(3):159-169..
|
22. |
RBE C E, WILFERT F, UTHE D, et al. Modulation of radiationinduced tumor necrosis factor α (TNF-α) expression in the lung tissue pentoxifylline[J]. Radiother Oncol,2002,64(2):177-187.
|
23. |
RUIZORTEGA M, LORENZO O, SUZUKI Y, et al. Proinflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens,2001,10(3):321-329..
|
24. |
YAO H W, MAO L G, ZHU J P. Protective effects of pravastatin in murine lipopolysaccharideinduced acue lung injury[J]. Clin Experiment Pharmacol Physiol,2006,33(9):793-797..
|
25. |
GRIP O, JANCIAUSKIENE S, LINDGREN S. Pravastatin downregulates inflammatory mediators in human monocytes in vitro[J]. Eur J Pharmacol,2000,410(1):83-92..
|
26. |
AMATO R J. Thalidomide: an antineoplastic agent[J]. Curr Oncol Rep,2002,4(1):56-62..
|
27. |
MOREIRA A L, SAMPAIO E P, ZMUIDZINAS A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation[J]. J Exp Med,1993,177(6):1675-1680. doi: 10.1084/jem.177.6.16A75..
|
28. |
ROCHA A C, FERNANDES E S, QUINTO N L, et al. Relevance of tumour necrosis factorα for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw[J]. Br J Pharmacol,2006,148(5):688-695..
|
29. |
MUKHOPADHYAY S, HOIDAL J R, MUKHERJEE T K. Role of TNFα in pulmonary pathophysiology[J]. Respir Res,2006,7(1):125-127..
|
30. |
GEARING A J, BECKETT P, CHRISTODOULOU M, et al. Processing of tumour necrosis factoralpha precursor by metalloproteinases[J]. Nature,1994,370(6490):555-557..
|
31. |
CORBEL M, LANCHOU J, GERMAIN N, et al. Modulation of airway remodelingassociated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice[J]. Eur J Pharmacol,2001,426(1-2):113-121..
|
32. |
EBERT E C. Infliximab and the TNFα system[J]. Am J Phisiol Gastrointest Liver Physiol,2009,296(3):G612-620..
|
33. |
MUTLU G M, MUTLU E A, BELLMEYER A, et al. Pulmonary adverse events of antitumor necrosis factorα antibody therapy[J]. Am J Med,2006,119(8):639-646; Comment in: Am J Med,2007,120(12):e21; author reply e23..
|